top stories

Pfiz­er gets an FDA win in he­mo­phil­ia af­ter a rough week

12 hours ago
R&D
Pharma
FDA+

Stealth Bio­Ther­a­peu­tics CEO dis­cuss­es sur­prise ad­comm sup­port for ul­tra-rare dis­ease drug

13 hours ago
People
FDA+

Val­ne­va and Pfiz­er eye 2027 launch for part­nered Ly­me dis­ease vac­cine

12 hours ago
Pharma
Marketing

Latest

Sanofi lands on pri­vate eq­ui­ty firm CD&R as po­ten­tial buy­er of con­sumer health unit

13 hours ago
Deals
Pharma

Te­va to pay $450M to set­tle al­le­ga­tions of kick­backs and gener­ic drug price-fix­ing

14 hours ago
Pharma
Law

Eu­ro­pean drug­mak­ers look to reshore man­u­fac­tur­ing but warn of price hikes

15 hours ago
Pharma
Manufacturing

Per­spec­tive’s ear­ly da­ta on lead-based ra­dio­phar­ma as­set sug­gest low­er dose did bet­ter

16 hours ago
R&D
see latest stream
People

Turn­stone re­jigs staff and ex­ec team, eas­es pre­clin­i­cal work as cash runs low

16 hours ago

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Yesterday

For­mer Pfiz­er CEO and CFO flip on ac­tivist and say they now sup­port com­pa­ny

2 days ago
Financing

VC firm tar­gets $35M sec­ond fund to back star­tups led by sci­en­tists

16 hours ago

Biotech star­tups Up­stream and CAMP4 price Fri­day IPOs

Yesterday

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

Yesterday
Startups

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Yesterday

Su­ki nabs $70M Se­ries D to arm doc­tors with AI tools

Yesterday

Pure­spring nabs $105M to take gene ther­a­py in­to the clin­ic as IgAN field ma­tures

3 days ago
Deals

Sen. War­ren urges FTC to ‘care­ful­ly scru­ti­nize’ No­vo-Catal­ent deal over com­pe­ti­tion con­cerns

Yesterday

AI biotechs Re­cur­sion and Ex­sci­en­tia first held deal talks in 2022

Yesterday

Spa­tial bi­ol­o­gy com­pa­nies Viz­gen and Ul­tivue merge amid on­go­ing law­suits

2 days ago

In FocusSee all

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

4 weeks ago
People

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

Last month
R&D
AI

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

Last month
R&D

The obe­si­ty drug race is be­ing fought on the man­u­fac­tur­ing floor as GLP-1 ri­vals make plans to catch lead­ers

2 months ago
Pharma
Manufacturing

Endpoints Standouts

How the world's biggest phar­ma and biotech com­pa­nies paid their typ­i­cal work­er in 2023

3 months ago
People
Pharma

In biotech's un­even re­cov­ery, 50 star­tups raised megarounds in first half of 2024

3 months ago
Financing
Startups

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

3 months ago
People
Special

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

3 months ago
Pharma
Cell/Gene Tx

Peer review See all

Oct
11

Lil­ly fol­lows the trend of new AI hires; Pfiz­er fills key UK po­si­tion as ac­tivist hub­bub swells

Oct
4

Af­ter $14B ex­it, Karuna co-founder finds next bet; Ex-Re­genxbio CEO Ken Mills heads to Tag­works

Sep
27

Steve Davis leaves Aca­dia, re­placed by Bris­tol My­ers alum; For­mer J&J ex­ec to lead R&D at No­vavax

Sep
20

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

Sep
13

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Pharma channel feed

20 hours ago

Ex­clu­sive: PhRMA at­tacks fed­er­al gov­ern­men­t's re­sponse to re­bate mod­el for 340B

The phar­ma in­dus­try’s DC-based lob­by­ing group urged the fed­er­al gov­ern­ment on Fri­day to get on board with al­ter­na­tive mod­els for 340B drug price dis­counts.

READ MORE

Up­dat­ed: FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Yesterday
FDA+

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

2 days ago
FDA+
latest in Pharma

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

2 days ago

Ma­jor PBMs call for re­mov­ing three FTC com­mis­sion­ers from in­sulin law­suit

2 days ago
Law
Health Tech

Zealand Phar­ma hit with sec­ond CRL for glucagon re­cep­tor ag­o­nist

2 days ago
FDA+
Manufacturing

GSK's RSV vac­cine Arexvy shows long-term pro­tec­tion in Phase 3 tri­al

3 days ago
R&D

Pfiz­er culls RSV treat­ment from Re­Vi­ral ac­qui­si­tion

3 days ago
R&D
see latest stories

Marketing channel feed

3 weeks ago

UK watch­dog crit­i­cizes Mod­er­na for Covid-19 tri­al's use of What­sApp to dan­gle pay­ments to chil­dren

The UK's phar­ma mar­ket­ing watch­dog, the Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty, is tak­ing is­sue with the way Mod­er­na al­leged­ly sought to in­crease par­tic­i­pa­tion in a Covid-19 ...

READ MORE

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

5 weeks ago
Pharma
FDA+

Up­dat­ed: Madri­gal fi­nal­ly re­veals first wave of sales for MASH drug Rezd­if­fra

2 months ago
Pharma
latest in Marketing

RSV mar­ket pres­sure leads to slow­er launch for Mod­er­na's vac­cine

2 months ago
Pharma

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

5 months ago
Financing

From the ed­i­tor: Our fi­nal edi­tion of End­points Mar­ket­ingRx

5 months ago
Editor's note

Mar­ket­ingRx roundup: Mod­er­na de­buts so­cial me­dia sci­ence se­ries; Boehringer ex­pands NY men­tal health ex­hib­it

5 months ago
Pharma

Re­al Chem­istry de­buts a one-stop dash­board for all things GLP-1

5 months ago
Pharma
see latest stories

FDA+ channel feed

Yesterday

FDA ad­comm sup­ports first po­ten­tial drug for ul­tra-rare, fa­tal Barth syn­drome

Heart­break­ing anec­dotes from the pa­tients, par­ents and doc­tors of chil­dren with the ul­tra-rare and fa­tal Barth syn­drome won over an FDA ad­vi­so­ry com­mit­tee on Thurs­day, like­ly set­ting up a ...

READ MORE

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Yesterday
R&D

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

2 days ago
People
Law
latest in FDA+

Cov­er­ing obe­si­ty drugs could cost Medicare $35B by 2034, CBO says

2 days ago

FDA again rais­es doubts on Stealth's ul­tra-rare dis­ease drug ahead of ad­comm

3 days ago

Many drug price pro­pos­als from can­di­dates and Con­gress won't have much ef­fect, analy­sis finds

4 days ago
Law

BAR­DA doles out $72M to Sanofi, GSK and CSL for bird flu vac­cine sup­ply

Last week
Pharma

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

Last week
Pharma
see latest stories

Manufacturing channel feed

Yesterday

Bax­ter plots re­cov­ery af­ter Hur­ri­cane He­lene, Mil­li­pore­Sig­ma’s €290M fa­cil­i­ty

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

READ MORE

Clients add pres­sure to CD­MOs to source raw ma­te­ri­als out­side of Chi­na, ex­ecs say

Yesterday
China

Jim Wil­son se­cures $100M for glob­al ap­proach aimed at re­viv­ing gene ther­a­py field

3 days ago
Deals
Discovery
latest in Manufacturing

No­vo and Lil­ly out­line plans to mit­i­gate dis­rup­tions from US port strikes

Last week
Pharma

Pfiz­er lays off staff in Ire­land; Bax­ter clos­es NC fa­cil­i­ty due to hur­ri­cane dam­age

Last week

Gilead li­cens­es HIV shot to six gener­ic man­u­fac­tur­ers, but falls short of ac­cess sought by ad­vo­cates

Last week
Pharma

J&J bud­gets over $2B for new North Car­oli­na bi­o­log­ics fa­cil­i­ty

Last week
Pharma

Lil­ly in­vests $4.5B in new In­di­ana site to bring clin­i­cal man­u­fac­tur­ing in-house

Last week
R&D
Pharma
see latest stories
A service from the Financial Times